FIELD: biotechnologies.
SUBSTANCE: modified capsular saccharide includes linker of the following formula: -A-N(R1)-L-M (I). With that, A represents -C(O)- or -OC(O)-. R1 is chosen from H or C1-C6-alkyl. L represents group of C1-C12-alkene. M represents a masked aldehyde group. Besides, the invention proposes other versions of modified saccharide, versions of a saccharide modification method, a conjugate of saccharide-protein and a pharmaceutical composition. Preferably, a new linker is used to obtain saccharide conjugates Neisseria meningitidis of serogroup A.
EFFECT: invention allows obtaining conjugates with a new linker, which have improved immunising capacity.
10 cl, 3 dwg
Authors
Dates
2014-10-27—Published
2008-12-19—Filed